Table 3.
Summarised course of disease in 6 patients with sporadic medullary thyroid carcinoma (sMTC) and in 1 patient with MEN2a.
| Patient | Period elapsed after MTC diagnosis [months] | Tumor burden/Progress according to RECIST | ECOG status at therapy initiation | Therapy duration[months] | Reason to discontinue vandetanib | Therapy-pause duration until progression [months] | CDT at progression or end of observation | Intervention | Status |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 252 | Moderate / yes | 0 | 73 | Duration vs. concern about toxicity | Ongoing (47 months, SD) |
> 2 | – | SD |
| 2 | 76 | High / no | 0 | 58 | Duration vs. concern about toxicity | Ongoing (61 months, SD) |
> 2 | – | SD |
| 3 | 102 | High / yes | 0 | 7 | Patient´s will, AE | 9 (PD) | < 2 | Re-start declined | Dead 6 months after PD; 15 months after TKI pausation |
| 4 | 47 | Moderate / yes | 0 | 87 | Duration vs. concern about toxicity | 45 (PD) | < 2 | Re-start vandetanib | SD in latest scan 29 months after re-start of TKI |
| 5 | 87 | High / yes | 0 | 12 | AE | 52 (PD) | >2, but CEA-DT critical (2.1 yrs) | Re-start vandetanib, | SD in latest scan 12 months after re-start of TKI |
| 6 | 54 | High / yes | 1 | 38 | AE | 5 (PD) | < 2 | Re-start declined | Dead 2 months after PD; 7 months after TKI pausation |
| 7 | 31 | High / yes | 0 | 36 | AE | 45 (PD) | < 2 | Enrollment in clinical trial | SD |
Indication for TKI therapy with vandetanib. Tumour burden (high: progressive distant metastasis; moderate: progressive locoregional metastasis), therapy duration, reason to discontinue therapy, therapy pause duration until progression or end of observation in 04/2021 along with CDT and current status are shown. SD, stable disease; PD, progressive disease; CDT, calcitonin doubling time; CEA-DT, carcinoembrionic antigen doubling time; AE, Adverse event.